Johnson & Johnson (NYSE:JNJ) Shares Acquired by Slagle Financial LLC

Slagle Financial LLC raised its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 102.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,926 shares of the company’s stock after buying an additional 13,091 shares during the quarter. Slagle Financial LLC’s holdings in Johnson & Johnson were worth $4,064,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in Johnson & Johnson by 16.4% during the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock valued at $3,764,852,000 after purchasing an additional 3,391,657 shares in the last quarter. Twin Focus Capital Partners LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $611,000. Richardson Financial Services Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth $54,000. Fortis Group Advisors LLC boosted its holdings in Johnson & Johnson by 39.9% during the fourth quarter. Fortis Group Advisors LLC now owns 3,494 shares of the company’s stock valued at $545,000 after acquiring an additional 996 shares during the period. Finally, Northwest Bank & Trust Co bought a new stake in Johnson & Johnson during the fourth quarter valued at about $223,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a report on Tuesday, June 4th. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Bank of America reduced their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Finally, The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective on the stock. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $174.07.

Get Our Latest Stock Analysis on JNJ

Johnson & Johnson Stock Performance

Shares of JNJ traded up $0.09 during mid-day trading on Friday, hitting $145.54. 4,075,342 shares of the company traded hands, compared to its average volume of 7,121,075. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The stock has a market cap of $350.27 billion, a price-to-earnings ratio of 9.07, a P/E/G ratio of 2.42 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The stock has a 50-day moving average price of $148.38 and a two-hundred day moving average price of $154.71.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same period last year, the firm earned $2.68 EPS. The company’s revenue was up 2.3% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a $1.24 dividend. The ex-dividend date was Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.41%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 30.92%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.